Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285323 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 464
- Enrollment target
NCT01285323 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 464 participants.
The verdict
NCT01285323, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 464 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
Interventions
- DRUG Placebo
- DRUG Reslizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285323
The ClinicalTrials.gov registry entry for NCT01285323 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01285323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285323 about?
NCT01285323 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma". The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
What is the current status of trial NCT01285323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 464 participants. The study started on 2011-03. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01285323?
The interventions under investigation include: Placebo (DRUG), Reslizumab (DRUG).
Who is sponsoring clinical trial NCT01285323?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.